Psyched Wellness increases its bought deal offering from CAD$3 million to CAD$5.5 million.

The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilize psychedelics. 

Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.

Phoenix, Arizona–(Newsfile Corp. – January 20, 2021) – The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.

The Canadian R&D company Entheon Biomedical has set out to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT) in treating addiction disorders. Specifically, the company has commissioned a clinical trial investigating the safety and efficacy of using intravenous DMT.

A novel Australian trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics.

The UK-based Beckley Foundation is a psychedelics non-profit founded over 20 years ago that is having an increasing impact on the Psychedelics Revolution.

Mind Cure has upsized its bought deal financing by DOUBLE to CAD$20 million.

Numinus announces the listing of its latest series of warrants for public trading, under the symbol “NUMI.WS”. Warrants have an exercise price of CAD$0.90 and are valid until December 29, 2022.

Psyched Wellness announces a CAD$3 million bought deal with units priced at CAD$0.31.